Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-11
DOI
10.3389/fonc.2020.587671
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer
- (2020) Tomoko Shibayama et al. BREAST CANCER RESEARCH AND TREATMENT
- GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models
- (2020) Shanchun Guo et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
- (2020) Thomas L. Gonzalez et al. BREAST CANCER RESEARCH AND TREATMENT
- A single droplet digital PCR for ESR1 activating mutations detection in plasma
- (2020) Emmanuelle Jeannot et al. ONCOGENE
- Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer
- (2020) Nanae Masunaga et al. Translational Oncology
- Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
- (2020) Wenzhen Zhu et al. OncoTargets and Therapy
- Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer
- (2020) Hao Liao et al. Cancer Management and Research
- Circulating tumor DNA analysis in breast cancer: is it ready for prime-time?
- (2019) Giuseppe Buono et al. CANCER TREATMENT REVIEWS
- Non-invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients
- (2019) Shunying Li et al. Thoracic Cancer
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
- (2019) Jingyu Liu et al. Journal of Translational Medicine
- Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
- (2019) Dabo Zhou et al. Translational Oncology
- ESR1 mutations in breast cancer
- (2019) Derek Dustin et al. CANCER
- Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
- (2019) Corinna Keup et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Selective oestrogen receptor degraders in breast cancer
- (2019) Andrea Gombos CURRENT OPINION IN ONCOLOGY
- Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
- (2019) Qianwei Ye et al. Molecular Cancer
- An evaluation of fulvestrant for the treatment of metastatic breast cancer
- (2019) Mohsin Soleja et al. EXPERT OPINION ON PHARMACOTHERAPY
- Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil
- (2019) Tomás Reinert et al. Journal of Oncology
- Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)
- (2019) Lorenzo Gerratana et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study
- (2019) Xuelu Li et al. Translational Oncology
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer
- (2018) O. Nordgård et al. BRITISH JOURNAL OF SURGERY
- Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines
- (2018) L. Gelsomino et al. CANCER LETTERS
- Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer
- (2018) Tomás Reinert et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Acquired resistance to aromatase inhibitors: where we stand!
- (2018) Tiago Vieira Augusto et al. ENDOCRINE-RELATED CANCER
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
- (2018) Jesse J. Salk et al. NATURE REVIEWS GENETICS
- Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes
- (2018) Shanhang Jia et al. ONCOLOGY
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
- (2018) Ben O’Leary et al. Nature Communications
- High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
- (2018) Laura Lupini et al. Scientific Reports
- Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
- (2018) Dara S. Ross et al. MODERN PATHOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
- (2018) Kai Zhang et al. Cancer Management and Research
- Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer
- (2018) Claudia Busonero et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
- (2018) Sean W Fanning et al. eLife
- Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
- (2018) Luis M. Seijo et al. Journal of Thoracic Oncology
- Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
- (2017) Takashi Takeshita et al. Translational Oncology
- ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling
- (2016) Luca Gelsomino et al. BREAST CANCER RESEARCH AND TREATMENT
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator
- (2016) Jiawang Liu et al. ACS Medicinal Chemistry Letters
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
- (2016) Florian Clatot et al. Oncotarget
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
- (2015) David Sefrioui et al. INTERNATIONAL JOURNAL OF CANCER
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity
- (2015) Bruno M. Simões et al. Cell Reports
- Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?
- (2014) M. Ignatiadis et al. ANNALS OF ONCOLOGY
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Investigation of Estrogen Receptor (ESR1) for Breast Cancer from Traditional Chinese Medicine
- (2014) Tzu-Chieh Hung et al. Biomed Research International
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The renaissance of endocrine therapy in breast cancer
- (2013) Nicole Williams et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology
- (2013) A. A. Belov et al. Cold Spring Harbor Perspectives in Biology
- Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
- (2012) Andrea Cavazzoni et al. CANCER LETTERS
- Cell Plasticity and Heterogeneity in Cancer
- (2012) N. D. Marjanovic et al. CLINICAL CHEMISTRY
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition
- (2012) Dimitrios Zardavas et al. CURRENT OPINION IN ONCOLOGY
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)
- (2010) S. Ohno et al. ANNALS OF ONCOLOGY
- Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
- (2010) Kirsten Vang Nielsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
- (2010) H. Harrison et al. CANCER RESEARCH
- Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer
- (2009) Ruth E. Board et al. Annals of the New York Academy of Sciences
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor
- (2008) D. J Kojetin et al. ENDOCRINE-RELATED CANCER
- Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
- (2008) Madhuri Kakarala et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started